PS 001
Alternative Names: PS-001 - Purespring TherapeuticsLatest Information Update: 08 Jun 2024
At a glance
- Originator Purespring Therapeutics
- Class Gene therapies; Urologics
- Mechanism of Action Gene transference; NPHS2 protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Nephrotic syndrome
Most Recent Events
- 30 May 2024 Pharmacodynamics and adverse events data from the preclinical studies in Nephrotic syndrome release by Purespring Therapeutics
- 24 May 2024 Preclinical trials in Nephrotic syndrome in United Kingdom (Parenteral) before May 2024
- 24 May 2024 Purespring Therapeutics plans a clinical trial for kidney disorders